left-arrow right-arrow pinterest facebook google_plus linkedin

Lung Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.


Alliance A081105

Status: Recruiting | Phase III

Official Title: Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Study Purpose: To determine if it is beneficial or not to add an investigational drug, erlotinib, following the standard chemotherapy for subjects with early stage non-small cell lung cancer that has been surgically removed. Learn more


Alliance A151216

Status: Recruiting | Phase III 

Official Title: Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Study Purpose: To study the genes of tumor cells to determine if these results will help physicians select the best treatment options for subjects with genetic changes. Learn more.


Alliance A211401

Status: Recruiting | Phase III

Official Title: Reducing surgical complications in newly diagnosed lung cancer patients who smoke cigarettes.

Study Purpose: The purpose of this study is to see if complications after sugery can be reduced by helping patients stop smoking with a drug called varenicline (also called chantix) and using National Cancer Institute (NCI) Tobacco Quitline for counseling. This study will see how well the drug varenicline helps patients stop smoking by comparing it to a placebo (a pill that contains no active drug). Learn more


Alliance A221504

Status: Recruiting | Phase II

Official Title: A Randomized, Double-Blind, Placebo-Controlled Pilot Study Of An Oral, Selective Peripheral Opioid Receptor Antagonist In Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)

Study Purpose: To determine feasibility and safety of long-term administration of two doses of a peripheral opioid receptor antagonist in patients with advanced NSCLC receiving first-line pemetrexed-based chemotherapy. Learn more.


Biodesix, Inc. BDX-00146

Status: Recruiting | Phase Not Applicable

Official Title: An observational study assessing the clinical effectiveness of the VeriStrat test and validation immunotherapy tests in subjects with non-small cell lung cancer.

Study Purpose: To collect information about how your study doctor uses the results of the VeriStrat blood test to choose treatment for your NSCLC. Learn more


CTSU E4512

Status: Recruiting | Phase III

Official Title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Study Purpose: To determine if patients with early stage non-small cell lung cance an investigational drug, crizotinib, following the standard chemotherapy for subjects with early stage non-small cell lung cancer that has been surgically removed. Learn more


CTSU LungMAP

Status: Recruiting | Phase II/III

Official Title: Targeted Treatment for Advanced Non-small Cell Lung Cancer

Study Purpose: The overall purpose of this study to find out if a targeted or immunotherapy treatment will have an effect on specific genes and proteins in your tumor. Learn more


ECOG-ACRIN EA5162

Status: Suspended | Phase II

Official Title: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR

Study Purpose: To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions. Learn more.


ECOG-ACRIN EA5163

Status: Recruiting|Phase III 

Official Title: A randomized, phase III study of firstline immunotherapy alone or in combination with chemotherapy in induction/maintenance or postprogression in advanced nonsquamous non-small cell lung cancer (NSCLC) with immunobiomarker SIGNature-driven analysis. 

Study Purpose: To find out whether either of these two usual approaches to treating your type of cancer is better or worse than the other. Learn more


Genentech GO40241

Status: Recruiting |Phase III

Official Title: A Phase III, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer

Study Purpose: To evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab in combination with platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in patients with resectable non-small cell lung cancer. Learn more


NRG LU003

Status: Recruiting | Phase III

Official Title: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-Squamous Non-Small Cell Lung Cancer

Study Purpose: This study has a screening part and a treatment part. The purpose of this initial screening is to test your tumor to find out if it has a specific mutation. The purpose of the treatment part of the study is to learn if a gene mutation is helpful to decide which different ALK targeting drug to give you compared to the usual treatment of chemotherapy and/or another ALK inhibitor not based on gene mutations. Learn more


NRG-LU005

Status: Recruiting | Phase II/III 

Official Title: Limited stage small cell lung cancer (LS-SCLC): A Phase II/III randomized study of chemoradiation versus chemoradiation plus atezolizumab.

Study Purpose: Compare progression free survival and overall survival for patients with LS-SCLC treated with chemoradiation +/- atezolizumab.  Learn more


PACIFIC-4/RTOG-3515

Status: Pending | Phase III 

Official Title: A phase III, randomized, placebo-controlled, double-blind, multi-center, international study of durvalumab following stereotactic body radiation therapy (SBRT) for the treatment of patients with unresected stage I/II, lymph-node negative non-small cell lung cancer.

Study Purpose: The reason for the study is to find out more effective treatment for stage I/II NSCLC following stereotactic body radiation therapy, which is a standard treatment for patients with your condition. Learn more


RTOG 0538/CALGB 30610

Status: Recruiting | Phase III

Official Title: Phase III Comparison Of Thoracic Radiotherapy Regimens In Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin Or Carboplatin And Etoposide

Study Purpose: To determine if high dose radiotherapy given over a shorter period of time (3 weeks) is more effective than standard dose given over 7 weeks. Learn more.